Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Raven biotechnologies has entered into an agreement with Monogram Biosciences, under which Monogram will evaluate selected Raven monoclonal antibodies for use with its VeraTag technology for diagnosis of cancer.
Subscribe to our email newsletter
The Raven technology platform has generated well-characterized, high-affinity monoclonal antibodies to proteins on the cell surface that can be used to quickly identify and validate targets. The platform has delivered an extensive library of antibodies targeting novel and recognized antigens. Raven is initially focusing on antibody-based therapeutics targeting lung, colon, pancreatic, prostate, breast, and ovarian cancer.
George Schreiner, CEO of Raven, said: “Through our collaboration with Monogram we hope ultimately to accelerate the development of targeted oncology therapeutics.”